Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-26T08:46:06.770Z Has data issue: false hasContentIssue false

P0137 - A double-blind randomized placebo-controlled study of relapse predictors in remitted first-episode psychosis patients

Published online by Cambridge University Press:  16 April 2020

L.M. Hui
Affiliation:
Department of Psychiatry, University of Hong Kong, Hong Kong, Hong Kong
Y.H. Chen
Affiliation:
Department of Psychiatry, University of Hong Kong, Hong Kong, Hong Kong
M. Lam
Affiliation:
Department of Psychiatry, Tai PO Hospital, Hong Kong, Hong Kong
C.W. Law
Affiliation:
Department of Psychiatry, Queen Mary Hospital, Hong Kong, Hong Kong
P.Y. Chiu
Affiliation:
Department of Psychiatry, Queen Mary Hospital, Hong Kong, Hong Kong
W.S. Chung
Affiliation:
Department of Psychiatry, Tai PO Hospital, Hong Kong, Hong Kong
S. Tso
Affiliation:
Department of Psychiatry, Castle Peak Hospital, Hong Kong, Hong Kong
P.F. Pang
Affiliation:
Department of Psychiatry, Tai PO Hospital, Hong Kong, Hong Kong
K.T. Chan
Affiliation:
Department of Psychiatry, Castle Peak Hospital, Hong Kong, Hong Kong
F. Mo
Affiliation:
Department of Psychiatry, Tai PO Hospital, Hong Kong, Hong Kong
P.M. Chan
Affiliation:
Department of Psychiatry, Kwai Chung Hospital, Hong Kong, Hong Kong
S.F. Hung
Affiliation:
Department of Psychiatry, Kwai Chung Hospital, Hong Kong, Hong Kong
W.G. Honer
Affiliation:
Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Medication discontinuation in remitted single episode patients after a period of maintenance therapy is a major clinical decision and thus the identification of risk factors controlling for medication status is important.

Methods:

Following a first/single episode with DSM-IV schizophrenia and related psychoses, remitted patients who had remained well on maintenance medication for at least one year were randomized to receive either maintenance therapy (with quetiapine 400 mg/day), or placebo for 12 months.

Results:

178 patients were randomized. Relapse rates were 33.7% (30/89) in maintenance group and 66.3% (59/89) in placebo group. Potential predictors were initially identified in univariate Cox regression models (p<0.1) and were subsequently entered into a multivariate Cox regression model for measuring the relapse risk. Significant predictors included patients on placebo (hazard ratio, 0.41; CI, 0.25 – 0.68; p=0.001); having more pre-morbid schizotypal traits (hazard ratio, 2.32; CI, 1.33 – 4.04; p=0.003); scoring lower in the logical memory test (hazard ratio, 0.94; CI, 0.9 – 0.99; p=0.028); and having more soft neurological signs (disinhibition) (hazard ratio, 1.33; CI, 1.02 – 1.74; p=0.039).

Conclusions:

Relapse predictors may help to inform clinical decisions about discontinuation of maintenance therapy specifically for patients with a first/single episode psychosis following at least one year of maintenance therapy.

Acknowledgement:

We are grateful to Dr TJ Yao at the Clinical Trials Center, University of Hong Kong, for statistical advice. The study was supported by investigator initiated trial award from AstraZeneca and the Research Grants Council Hong Kong (Project number: 765505).

Type
Poster Session I: Schizophrenia and Psychosis
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.